C - Chemistry – Metallurgy – 07 – K
Patent
C - Chemistry, Metallurgy
07
K
C07K 16/30 (2006.01) A61K 39/395 (2006.01) A61P 17/06 (2006.01) A61P 25/28 (2006.01) A61P 35/00 (2006.01) G01N 33/68 (2006.01)
Patent
CA 2582683
The present invention relates to a particularly advantageous antibody, antibody fragment or derivative thereof, which specifically binds to/interacts with at least one epitope of the extracellular or intracellular domain of the mammalian EAG1 ion channel and to nucleic acid molecules encoding the same and to vectors comprising said nucleic acid molecules. The invention additionally relates to methods for the preparation of said antibody, antibody fragments or derivatives thereof and to pharmaceutical compositions comprising the same. Furthermore, the use of said antibody, antibody fragment or derivative thereof and also diagnostic compositions comprising said components are disclosed in the specification. The invention also relates to a method of assessing for the presence of EAG1 expressing cells and for a method of blocking EAG1 function in said cells. The invention further relates to a method of treating diseases with the help of said antibody or antibody fragment or derivative thereof.
La présente invention concerne un anticorps particulièrement avantageux, un fragment d'anticorps ou un dérivé de celui-ci qui se lie/interagit de manière spécifique avec au moins un épitope du domaine extracellulaire ou intracellulaire du canal ionique EAG1 mammifère, ainsi que des molécules d'acide nucléique codant celui-ci et des vecteurs comprenant lesdites molécules d'acide nucléique. Cette invention concerne aussi des procédés pour préparer ledit anticorps, fragments d'anticorps ou dérivés de celui-ci, ainsi que des compositions pharmaceutiques comprenant celui-ci. Elle concerne aussi l'utilisation dudit anticorps, fragment d'anticorps ou dérivé de celui-ci, ainsi que des compositions diagnostiques comprenant lesdits composants. Ladite invention concerne également un procédé pour évaluer la présence de cellules exprimant EAG1, ainsi qu'un procédé pour bloquer la fonction de EAG1 dans lesdites cellules. En outre, cette invention concerne un procédé pour traiter des maladies à l'aide dudit anticorps, fragment d'anticorps ou dérivé de celui-ci.
Dehne Kerstin
Gomez-Varela David
Knoetgen Hendrik
Pardo Luis A.
Rothe Mike
Goudreau Gage Dubuc
Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.v.
U3 Pharma Ag
LandOfFree
Novel antibodies directed to the mammalian eag1 ion channel... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Novel antibodies directed to the mammalian eag1 ion channel..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Novel antibodies directed to the mammalian eag1 ion channel... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1445566